Algeria African Region

I. Epidemiological profile Population (UN Population Division) 2017 % Parasites and vectors Number of active foci 0 - Major plasmodium species: P.falciparum: 0 (%) , P.vivax: 0 (%) Number of people living within active foci 0 - Major anopheles species: An. multicolor, An. labranchiae, An. sergentii, An. hispaniola Malaria free (0 cases) 41.3M 100 Reported indigenous confirmed cases (health facility): 0 Total 41.3M Confirmed cases at community level: - Confirmed cases from private sector: - Indigenous deaths: 0

II. Intervention policies and strategies Yes/ Year Intervention Policies/Strategies Medicine Year adopted No adopted Antimalaria treatment policy ITN ITNs/LLINs distributed free of charge No 2000 First-line treatment of unconfirmed malaria - - ITNs/LLINs distributed to all age groups No - First-line treatment of P. falciparum - - IRS IRS is recommended Yes 1980 For treatment failure of P. falciparum - - DDT is used for IRS No - Treatment of severe malaria - - Larval control Use of Larval Control Yes - Treatment of P. vivax CQ - IPT IPT used to prevent malaria during pregnancy - - Dosage of primaquine for radical treatment of P. vivax 0.25 mg/Kg (14 days) Diagnosis Patients of all ages should receive diagnostic test - - Type of RDT used P.f + all species (Combo) Malaria diagnosis is free of charge in the public sector Yes 1968 Therapeutic efficacy tests (clinical and parasitological failure, %) Treatment ACT is free for all ages in public sector Yes - Medicine Year Min Median Max Follow-up No. of studies Species has never The sale of oral artemisinin-based monotherapies (oAMTs) - Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2017) been 1 2 3 allowed Insecticide class Years (%) sites Vectors Used Single dose of primaquine (0.25 mg base/kg) is used as Carbamates - - - No Yes - gametocidal medicine for P. falciparum Organochlorines - - - No Primaquine is used for radical treatment of P. vivax Yes - Organophosphates - - - No Pyrethroids - - - Yes G6PD test is a requirement before treatment with primaquine No - Directly observed treatment with primaquine is undertaken Yes - 1Percent of sites for which resistance confirmed and total number of sites that reported data (n) System for monitoring of adverse reaction to antimalarials 2Principal vectors that exhibited resistance No - exists 3Class used for malaria vector control in 2017 Surveillance ACD for case investigation (reactive) Yes - ACD at community level of febrile cases (pro-active) No - Mass screening is undertaken No - Uncomplicated P. falciparum cases routinely admitted Yes - Uncomplicated P. vivax cases routinely admitted Yes - Case and foci investigation undertaken Yes 1980 Case reporting from private sector is mandatory Yes -

III. Charts Sources of ﬁnancing Government expenditure by intervention in 2017 2'500k

2'000k

1'500k

1'000k Contribution($USm)

500k

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Insecticides & spray materials ITNs Diagnostic testing Others WHO/UNICEF USAID/PMI Worldbank (USD) Antimalarial medicines Monitoring and evaluation Global Fund (USD) Government contribution Human resources & technical assistance Management and other costs

IV. Coverage Coverage of ITN and IRS Cases tested 100 100

75 75

50 50 (%) Population

25 25

0 0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 At high risk protected with ITNs At high risk protected with IRS % of the population who slept under an ITN the previous night (survey) % of households with at least 1 ITN (survey Suspected cases tested

V. Impact Cases tested and treated in public sector Cases tracked 100% 100 100%

75% 75 75%

50% 50 50% (%) Cases (%) Cases

25% 25 25%

0% 0 0% 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Antimalarials distributed vs reported cases ACTs as % of all antimalarials received by <5 (survey) Primaquine distributed vs reported P. v. cases Case investigation rate Foci investigation rate ACTs distributed vs reported P. f. cases Reporting completeness

V. Impact Conﬁrmed malaria cases per 1000 and ABER Number of malaria cases 10 1 1000

8 0.8 750

6 0.6 ABER (%)

500 Cases

4 0.4 Positivity rate (%) Positivity

250

2 0.2

0 0 0

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total cases Imported cases Indigenous case (P. falciparum)) ABER Slide positivity rate RDT positivity rate Indigenous case (P. vivax))

World Malaria Report 2018